The coagulation system is central to the pathophysiology of acute lung injury. We have previously demonstrated that the anticoagulant activated protein C (APC) prevents increased endothelial permeability in response to edemagenic agonists in endothelial cells and that this protection is dependent on the endothelial protein C receptor (EPCR). We currently investigate the effect of APC in a mouse model of ventilator-induced lung injury (VILI). C57BL/6J mice received spontaneous ventilation (control) or mechanical ventilation (MV) with high (HVT; 20 ml/kg) or low (LVT; 7 ml/kg) tidal volumes for 2 h and were pretreated with APC or vehicle via jugular vein 1 h before MV. In separate experiments, mice were ventilated for 4 h and received APC 30 and 150 min after starting MV. Indices of capillary leakage included bronchoalveolar lavage (BAL) total protein and Evans blue dye (EBD) assay. Changes in pulmonary EPCR protein and Rhoassociated kinase (ROCK) were assessed using SDS-PAGE. Thrombin generation was measured via plasma thrombin-antithrombin complexes. HVT induced pulmonary capillary leakage, as evidenced by significant increases in BAL protein and EBD extravasation, without significantly increasing thrombin production. HVT also caused significant decreases in pulmonary, membrane-bound EPCR protein levels and increases in pulmonary ROCK-1. APC treatment significantly decreased pulmonary leakage induced by MV when given either before or after initiation of MV. Protection from capillary leakage was associated with restoration of EPCR protein expression and attenuation of ROCK-1 expression. In addition, mice overexpressing EPCR on the pulmonary endothelium were protected from HVT-mediated injury. Finally, gene microarray analysis demonstrated that APC significantly altered the expression of genes relevant to vascular permeability at the ontology (e.g., blood vessel development) and specific gene (e.g., MAPK-associated kinase 2 and integrin-␤6) levels. These findings indicate that APC is barrier-protective in VILI and that EPCR is a critical participant in APC-mediated protection. endothelial protein C receptor; mechanical stress; vascular barrier function; ventilator-induced lung injury ACUTE LUNG INJURY (ALI) is a devastating illness with an annual incidence of ϳ200,000 and a mortality of 40% (51). Most commonly seen in the setting of sepsis (9, 26, 50), ALI is a complex inflammatory syndrome marked by increased vascular permeability resulting in tissue edema and organ dysfunction (58). The vascular endothelium is a key target and critical participant in the pathogenesis of sepsis-induced organ dysfunction and is central to the pathophysiology of both sepsis and ALI. Unfortunately, recent insights into the mechanisms of ALI have not translated into improved therapy, and treatment remains largely supportive and dependent on mechanical ventilation (MV). However, MV can contribute to increases in vascular permeability, particularly at high tidal volumes, a phenomenon known as ventilator-induced lung injury (VILI), and a lung-protective strategy of ventilation aimed at minimizing alveolar overdistension attenuates the inflammatory response (47) and results in decreased mortality (3). Although the current understanding of the pathophysiology of VILI remains incomplete, a critical deleterious component of MV appears to be mechanical stress that, in experimental models, activates the GTPase Rho pathway and contributes to increased vascular permeability (7, 45). Rho-associated kinase (ROCK-1), the downstream effector of Rho in pulmonary endothelium, enhances myosin light chain phosphorylation and endothelial stress fiber formation, which leads to endothelial gap formation (60).
commonly seen in the setting of sepsis (9, 26, 50) , ALI is a complex inflammatory syndrome marked by increased vascular permeability resulting in tissue edema and organ dysfunction (58) . The vascular endothelium is a key target and critical participant in the pathogenesis of sepsis-induced organ dysfunction and is central to the pathophysiology of both sepsis and ALI. Unfortunately, recent insights into the mechanisms of ALI have not translated into improved therapy, and treatment remains largely supportive and dependent on mechanical ventilation (MV). However, MV can contribute to increases in vascular permeability, particularly at high tidal volumes, a phenomenon known as ventilator-induced lung injury (VILI), and a lung-protective strategy of ventilation aimed at minimizing alveolar overdistension attenuates the inflammatory response (47) and results in decreased mortality (3) . Although the current understanding of the pathophysiology of VILI remains incomplete, a critical deleterious component of MV appears to be mechanical stress that, in experimental models, activates the GTPase Rho pathway and contributes to increased vascular permeability (7, 45) . Rho-associated kinase (ROCK-1), the downstream effector of Rho in pulmonary endothelium, enhances myosin light chain phosphorylation and endothelial stress fiber formation, which leads to endothelial gap formation (60) .
It has become increasingly appreciated that a deficiency of regulatory proteins involved in coagulation, such as activated protein C (APC), participates in the widespread inflammation of sepsis and ALI (38, 59) and that treatment of patients with sepsis with the endogenous anticoagulant APC reduces mortality (6) . Although APC is known to have anticoagulant and anti-inflammatory properties, the exact mechanisms through which it benefits patients with severe sepsis (and potentially ALI) remain undefined. We (16) have previously demonstrated that APC enhances pulmonary endothelial barrier function in vitro via alterations in the endothelial cytoskeleton and that APC-mediated intracellular signaling and endothelial barrier protection is dependent on the APC receptor, the endothelial protein C receptor (EPCR).
Although APC is known to promote vascular integrity and improve survival in sepsis (6, 16) , a beneficial effect in ALI is unproven. Moreover, whether APC can attenuate the deleterious effects of MV remains unknown. We hypothesized that APC could be protective in VILI. Using a well-characterized murine model of ventilator-induced vascular leak (1, 35, 44) , we demonstrate that MV-mediated increases in pulmonary permeability are associated with increased expression of ROCK-1 and loss of pulmonary, membrane-bound EPCR. Furthermore, our results indicate that loss of pulmonary EPCR is critical to the generation of stress-mediated pulmonary vascular permeability; APC treatment attenuates both stretchmediated vascular leak and ROCK-1 expression and stabilizes pulmonary EPCR expression. Finally, microarray analysis of lung tissue identified several gene ontologies as well as specific genes that might be participating in APC-mediated vascular barrier protection.
MATERIALS AND METHODS
Johns Hopkins University Institutional Animal Care and Use Committee approved all animal protocols.
Experimental protocol and animal exposure to MV. Male C57BL/6J mice age 8 -10 wk (The Jackson Laboratory, Bar Harbor, ME) were studied in a pathogen-free facility. Animals were first anesthetized, underwent intubation, and were subjected to MV (Harvard Apparatus, Boston, MA) with room air for 0 h (sham) or 0.5-4 h with low (7 ml/kg; LVT) and high (20 ml/kg; HVT) tidal volumes. Animals were pretreated 1 h before MV with either human APC (100 g/kg iv; Eli Lilly, Indianapolis, IN) in a single bolus dose (APCtreated) or the equivalent volume phosphate-buffered saline (untreated). In separate experiments, animals were given APC at 30 and 150 min after initiation of MV and were ventilated for a total of 4 h. All animals were given a 500-l bolus of lactated Ringer solution intravenously at the initiation of MV to maintain adequate mean arterial blood pressure (ϳ80 Torr). The respiratory rate was set at 160 breaths/min for all tidal volumes, and the dead space was adjusted by increasing the length of ventilator tubing in the HV T group to maintain an arterial pH between 7.35 and 7.45. The adequacy of MV settings on gas exchange was confirmed in preliminary experiments in which arterial blood gases obtained via catheterization of a femoral artery and analyzed by automated blood gas analyzer (Instrumentation Laboratories, Lexington, MA) revealed stable levels of arterial oxygen and carbon dioxide and an arterial pH ranging between 7.35 and 7.45. No positive end-expiratory pressure (PEEP) was applied, and airway pressures, continuously measured during MV, revealed that end-expiratory pressures remained around 0 -2 cmH 2O throughout the 4-h period for both LV T and HVT. At the end of MV, the animals were administered an intraperitoneal lethal dose of the anesthetic agent before the lungs were harvested.
Assessment of pulmonary capillary permeability. Evans blue dye (EBD; 20 ml/kg) was injected into the external jugular vein 30 min before termination of the experiment to assess vascular leak as previously described (1, 35, 45) .
Bronchoalveolar lavage protein concentration. Bilateral bronchoalveolar lavage (BAL) was performed with 1 ml of saline for determination of BAL fluid protein concentration as previously described (45) .
SDS-PAGE and immunoblotting. Western blotting using EPCR antibody (R&D Systems, Minneapolis, MN) was performed as previously described after tissue was homogenized and quantified using a Bradford protein assay (18) . ROCK expression in lung tissue was assessed via Western blotting using a specific ROCK-1 or -2 antibody (BD Transduction Laboratories, Lexington, KY) as previously described (20) .
Membrane-fraction enrichment. To determine the effect of MV on surface EPCR expression, membrane enrichment was obtained as described previously (24, 32) and subjected to Western blotting as above.
Measurement of thrombin-antithrombin complexes.
Mice [wildtype (WT) and Tie2-EPCR] were exposed to 4-h MV with and without APC as above. Blood was drawn into syringes containing 3.2% citrate and 100 mM benzamidine and centrifuged at 3,000 rpm for 15 min. Thrombin-antithrombin complexes (TATc) were determined via commercially available ELISA (Enzygnost; Dade Behring).
Transcript profiling with Illumina oligonucleotide array. Illumina profiling was performed at the Lowe Family Genomics Core. The total lung mRNA was isolated from parenchymal tissues. The processed RNA (quality monitored on an Agilent 2100 Bioanalyzer) was hybridized to Mouse_Ref-8_V2 microarray (25,697 transcripts) , and hybridization signals were analyzed using BeadStudio version 1.5.0.34 software (Illumina). Resulting digitized matrix was processed by modified Illumina platform approach as described previously (23) . Briefly, the significance of hybridization signals was tested, and "Present" [BeadStudio detection (BSD) Ͻ 0.05] and "Absent" (BSD Ն 0.05) transcripts was identified. The chip background and brightness were computed using high quartile and whole set of Absent hybridization signals, respectively. The expression data were stratified by experimental conditions (n ϭ 3), and hybridization of each transcript was evaluated for each cluster. The transcripts that were Present and produced a signal at least twice as high as that of background in at least 2 of 3 hybridizations in any given group of mice were considered expressed. To normalize expression values between different BeadChips, each background adjusted value was divided by a corresponding chip brightness coefficient.
Computational identification of ventilation-affected candidate genes. Significance Analysis of Microarrays (SAM 2.20; Ref. 57) was conducted using full permutation of 3 control and 3 HVT or HVT ϩ APC samples (720 permutations) without application of arbitrary restrictions (34) . Genes with 50% changes in expression and 5% false discovery rate (FDR) were considered significantly affected by HVT or HVT ϩ APC.
Gene ontology analysis. The Affymetrix identities for the matching Illumina probe were retrieved from NetAffx (http://www.affymetrix. com). Affymetrix and Illumina probe identities were matched by gene symbols using Microsoft Access and corresponding Affymetrix identities assigned to probes that comprise the Mouse_Ref-8_V2 microarray. The MAPPFinder-compatible files were prepared using Gen-MAPP converting tool as we (21) described previously. This approach identified 9,188 genes linking 5,314 genes to known gene ontology term, of which 53 genes were affected by APC.
Statistics. Values are shown as means Ϯ SE, with n Ն 4 for each experimental condition. Data were analyzed by a one-way ANOVA with Bonferroni correction. Significance in all cases was defined as P Ͻ 0.05. For gene expression analysis, the SAM-generated q value was used, which represents the lowest FDR for a gene to be called significant (54) . The q value is an approximated equivalent of P value, adapted to the analysis of a large number of genes, and significance in transcriptional changes was considered as q Ͻ 5.
Gene ontologies that were represented by at least one APC-affected gene in the "child" node of a biological processes tree, three APCaffected genes (Ͼ5% of detected by MAPPFinder genes) in the "parental" node of the same tree, and z-score Ͼ1.96 were considered as significantly affected by APC.
RESULTS

Increased pulmonary vascular permeability in response to HV T .
We have previously demonstrated that 2-h HV T MV causes significant pulmonary vascular leakage compared with control, spontaneously breathing mice and mice exposed to LV T . However, the minimum duration of MV required to induce injury is unknown. To determine the time of onset of capillary vascular leak in response to MV, C57BL/6J mice were exposed to either HV T (20 ml/kg) or LV T (7 ml/kg) for 30 min to 2 h and compared with controls. Figure 1 demonstrates that 2 h of HV T , but not shorter times, caused significant pulmonary leak, as measured by increases in BAL total protein and lung tissue EBD extravasation. LV T failed to elicit increases in permeability over 2 h (data not shown).
Effect of APC on MV-mediated increases in lung vascular permeability. We (16) have previously reported that APC confers endothelial barrier protection in human pulmonary endothelial cells exposed to thrombin. Therefore, we tested whether APC could protect against mechanical stress-induced capillary leakage in vivo. Mice were ventilated for 2 h with tidal volumes of 20 ml/kg (HV T ), with or without pretreatment with APC (1 h before MV, 100 g/kg iv as described in MATERIALS AND METHODS), before measurement of BAL total protein and lung EBD extravasation. As shown in Fig. 2A , the increase in BAL total protein produced by HV T MV was significantly reduced by pretreatment with APC. Similarly, lung extravasation of EBD was significantly attenuated by pretreatment with APC ( Fig. 2B) . APC had no effect on BAL protein or EBD leak in unventilated mice (data not shown), and LV T MV showed no differences in measured indices of capillary permeability compared with control ( Fig. 2 ). These data indicate that APC is protective against the development of increased pulmonary capillary permeability in an in vivo model of mechanical injury.
We have previously shown that mechanical stress imparted by HV T MV [e.g., activation of signaling pathways such as p38 MAPK, inducible nitric oxide synthase, and xanthine oxidoreductase (1, 44) ] is an early phenomenon occurring within minutes of MV. Therefore, we sought to determine whether APC could be protective against vascular permeability after initiation of MV. Mice were ventilated for 4 h as described above, and APC treatment was given at 30 and 150 min after initiation of MV. As shown in Fig. 3 , treatment with APC resulted in significant attenuation of HV T -mediated vascular leak as measured by changes in BAL protein and EBD extravasation, consistent with a protective effect of APC on pulmonary vascular permeability after the onset of mechanical stress. At 4 h, LV T resulted in a small but significant increase in BAL protein but no increase in EBD extravasation. Delaying APC treatment beyond 30 min (e.g., 1 h or beyond) was not effective (results not shown).
Effect of MV and APC on lung EPCR. EPCR is the receptor for both protein C and APC and is an essential component in APC-mediated vascular protection (16) . Nonmechanical inflammatory stimuli have been shown to result in EPCR shedding from the endothelial cell surface (3, 10, 33, 52) . Whether a mechanical stimulus alters EPCR levels is unknown. To determine the effect of mechanical stress on EPCR expression in vivo, mice were exposed to 2-h HV T MV, following which, lung EPCR levels were assessed using SDS-PAGE and Western blotting with an EPCR-specific antibody. As shown in Fig. 4 , both 2 and 4 h of HV T MV resulted in decreased lung tissue EPCR expression, which was significantly attenuated by pretreatment with APC, whereas shorter exposure to HV T MV, and LV T of any duration had no effect on tissue EPCR. Taken together, these studies reveal that HV T MV results in decre- Fig. 1 . Two hours of mechanical ventilation are required to cause pulmonary injury. C57BL6/J mice were exposed to high (HVT; 20 ml/kg) and low (LVT; 7 ml/kg) tidal volumes for increasing durations, and indices of pulmonary injury were assessed using Evans blue dye (EBD) extravasation and bronchoalveolar lavage (BAL) protein measurement. Whereas HVT 30-and 60-min failed to elicit increases in pulmonary vascular injury, 120-min caused a significant increase in both BAL protein (A) and EBD extravasation (B) compared with control. LVT ventilation failed to cause increased BAL protein or EBD extravasation at any time point (data not shown). *P Ͻ 0.05 compared with control value; n ϭ 4 -6 for each group. Fig. 2 . Activated protein C (APC) attenuates mechanical ventilation (MV)-induced pulmonary injury. C57BL6/J mice were exposed to 120-min MV with 1-h pretreatment with APC (100 g/kg) or vehicle, and indices of pulmonary vascular injury were assessed using EBD leakage and BAL protein. Whereas 120 min of HVT results in significant increases in pulmonary injury, pretreatment with APC significantly attenuates HVT-mediated increases in BAL protein (A) and in EBD leakage (B). *P Ͻ 0.05 compared with control value; n ϭ 4 -6 for each group. LVT has no effect on EBD extravasation or BAL protein.
ments in lung tissue EPCR and increased pulmonary vascular permeability, whereas the barrier-protective administration of APC results in restoration of tissue EPCR.
Effect of MV and APC on lung tissue membrane EPCR. Although EPCR is expressed on the surface of endothelial cells, decreases in EPCR expression (as shown in Fig. 4 ) may result from changes in intracellular stores of EPCR rather than specific membrane expression. Moreover, we hypothesized that EPCR must be on the endothelial surface, available for APC ligation, to effect intracellular signaling. To assess endothelial surface EPCR expression, lung tissue collected from mice exposed to HV T MV with and without APC treatment, LV T , and spontaneously breathing controls was fractionated into membrane and cytosolic components. SDS-PAGE was done on the membrane fraction. As can be seen in Fig. 5 , HV T results in significant decreases in membrane EPCR compared with LV T and controls, which are restored to normal levels by pretreatment with APC. These findings demonstrate that mechanical stretch-induced pulmonary vascular injury is accompanied by specific loss of membrane EPCR, which can be prevented by APC.
Effect of MV on pulmonary vascular function and tissue EPCR levels in EPCR-overexpressing mice. We (16) have previously demonstrated that EPCR is a necessary participant in APC-mediated barrier protection in cultured endothelial cells. The association of increased murine pulmonary vascular permeability with loss of membrane EPCR further supports that intact membrane EPCR expression participates in APCmediated pulmonary vascular barrier protection. Mice that overexpress EPCR (Tie2-EPCR mice) on the endothelial surface, and obtained from a C57BL/6J background strain, have been shown to have higher circulating levels of APC and decreased mortality when exposed to lethal doses of LPS (36) . To define further the role of EPCR in VILI, we exposed Tie2-EPCR mice to HV T MV and measured indices of pulmonary vascular permeability. In contrast to WT mice, Tie2-EPCR mice exposed to HV T were significantly protected from MV-induced vascular permeability as measured by changes in Fig. 4 . HVT significantly reduces lung endothelial protein C receptor (EPCR) levels. Mice were exposed to 2-h HVT MV, following which, the lungs were harvested, and EPCR levels were determined using SDS-PAGE and Western blotting. Two hours of HVT MV results in significant reduction in lung tissue EPCR, whereas shorter time points fail to alter EPCR expression. However, pretreatment with APC (1 h, 100 g/kg) significantly attenuates MV-induced decreases in EPCR at 2 h. LVT did not cause reductions in EPCR at any time point. *P Ͻ 0.001 vs. control; †P Ͻ 0.01 HVT vs. HVT ϩ APC; n ϭ 4 -6 for each group. A: representative Western blots of EPCR and actin (control) expression. B: densitometric assessment of EPCR normalized to actin. RDU, relative densitometry units. Fig. 5 . MV-and APC-mediated changes in pulmonary EPCR expression are membrane-specific. To determine cellular localization of changes in EPCR, membrane enrichment of lung tissue from mice exposed to 2-h HVT and LVT was subjected to SDS-PAGE followed by Western blotting with an EPCRspecific antibody. HVT caused significant reductions in membrane EPCR, whereas pretreatment with APC (1 h, 100 g/kg) abrogated MV-mediated changes. *P Ͻ 0.05 compared with control value; n ϭ 4 -6 for each group. LVT caused no change in membrane EPCR compared with control. Cytosolic EPCR remained unchanged (data not shown). Fig. 3 . APC posttreatment attenuates MV-mediated increases in pulmonary vascular permeability. Mice were exposed to 4-h MV and treated with 100 g/kg APC or vehicle 30 and 150 min after initiation of ventilation. Vascular integrity was assessed using BAL protein (A) and EBD leakage (B). APC given after initiation of MV significantly attenuated increases in MV-induced vascular leak. *P Ͻ 0.05 HVT vs. control, LVT, and HVT ϩ APC; **P Ͻ 0.05 control vs. LVT and HVT ϩ APC; n ϭ 4 -6 for each group. LVT has no effect on EBD extravasation. BAL protein and EBD extravasation (Fig. 6) . The finding that EPCR overexpression confers enhanced barrier protection from MV compared with WT mice provides further evidence that EPCR is a critical participant in vascular barrier functional integrity.
ROCK expression in MV. Although cyclic stretch has been shown to activate Rho pathway signaling, the effect of HV T on Rho signaling and its downstream effector, ROCK, in vivo is unknown. Therefore, lung tissue from mice exposed to HV T with and without APC treatment was assessed via Western blotting. ROCK-1 expression was significantly increased in mice exposed to 4-h HV T compared with controls. APC treatment (30 and 150 min after initiation MV) significantly attenuated ROCK-1 expression in WT mice (Fig. 7A) . In contrast, ROCK-1 expression was only mildly and not significantly increased by HV T in Tie2-EPCR mice (Fig. 7B) . We saw no changes in ROCK-2 expression (data not shown).
Effect of MV on TATc. Given that ALI is characterized by enhanced coagulation, we tested whether there was increased thrombin production in our model and whether the APCmediated protection observed was a function of attenuating thrombin production. Thrombin generation in response to MV was assessed via plasma measurements of TATc as described in MATERIALS AND METHODS. Although intratracheal LPS (used as a positive control) caused a significant elevation in TATc (91.93 vs. 30.54 g/l control), HV T failed to increase TATc at 4 h in WT mice compared with controls (Fig. 8A) . APC treatment caused a reduction in TATc, however, this was not significant. Tie2-EPCR mice had significantly less TATc compared with WT (Fig. 8, B-D) and similarly had no increase in TATc in response to MV.
Differential pulmonary gene expression by MV and APC. Previous studies have reported that APC can influence expression of genes that might be relevant to lung injury (29) , however, how APC might affect changes in expression in the lung in response to mechanical stress is unknown. We have previously described broad changes in gene expression in mouse (43) and rat (41) models of VILI. Several VILI-related candidate genes common to the two animal models were significantly upregulated. These include particularly genes related to tissue remodeling, coagulation, regulation of inflammation, chemotaxis and cell motility, cell proliferation and adhesion, and redox signaling. To assess the specific effects of APC treatment on changes in gene expression in response to HV T MV exposure, we utilized Affymetrix gene expression profiling on whole lung RNA from mice exposed to 4-h HV T with and without APC treatment (provided at 30 and 150 min) Fig. 6 . EPCR overexpression protects from ventilator-induced lung injury (VILI). Tie2-EPCR mice that overexpress EPCR in the pulmonary endothelium were exposed to HVT for 2 h, and indices of pulmonary vascular permeability were assessed. Tie2-EPCR mice are protected from VILI as measured by BAL protein (A) and EBD extravasation (B). *P Ͻ 0.05 compared with control value; n ϭ 4 -6 for each group. WT, wild-type. Fig. 7 . Rho-associated kinase-1 (ROCK-1) expression in MV. Mice were exposed to 4-h HVT with and without APC, and ROCK-1 expression was assessed via Western blotting. Compared with controls (Ctrl), HVT significantly increased ROCK-1 expression in WT (A; P Ͻ 0.05) but not in Tie2-EPCR (B; P ϭ 0.16) mice. APC treatment resulted in significantly lower ROCK-1 expression in WT mice exposed to HVT MV compared with untreated mice (*P Ͻ 0.05 vs. control and HVT ϩ APC). n Ն 3 animals per group with representative blots shown. Shown are representative Western blots of ROCK-1 and actin (control) expression and densitometric assessment of ROCK-1 normalized to actin (n ϭ 3 for each condition) in WT (A) and Tie2-EPCR (B) mice. compared with controls. All genes were filtered to include those with a difference in gene expression between HV T alone vs. HV T ϩ APC of 1.5-fold or greater.
Individual genes were categorized into distinct biological pathways using MAPPFinder, a tool that combines annotations of the Gene Ontology (GO) Project with the free software package GenMAPP. As shown in Table 1 , GO analysis identified specific ontologies relevant to vascular permeability such as blood vessel development, blood vessel morphogenesis, cell adhesion, hemopoiesis, and inflammation, which were significantly affected by APC treatment. Moreover, expression analysis identified specific genes pertinent to endothelial biology and lung injury, such as MAPK-activated protein kinase-2 (MK2), integrin-␤ 6 , bone morphogenetic protein 1, and Bcl-2-like-1, for which expression was significantly decreased by APC treatment compared with HV T alone ( Table 2) .
DISCUSSION
ALI is characterized by pulmonary vascular permeability resulting in severe tissue inflammation, profound hypoxia, and respiratory failure requiring support with MV. However, it has become increasingly apparent, both in animal models and in humans, that MV, although necessary for life support, can directly injure the pulmonary vascular endothelium (14) resulting in loss of integrity of barrier function and formation of a protein-rich edema in the alveolar space.
We (16) have previously demonstrated that APC confers protection against the endothelial barrier-disrupting agonist thrombin in cultured pulmonary endothelial cells, an effect that is dependent on EPCR. Here, we build on those findings and report that APC protects against a murine model of pulmonary vascular permeability and that EPCR plays a critical role in vascular barrier protection in the intact animal. To test the effects of APC and EPCR expression on pulmonary endothelial integrity, we used a well-characterized model of mechanical stress-induced pulmonary vascular injury that does not rely on a second injurious stimulus, such as endotoxin or hyperoxia, and is characterized predominantly by pulmonary vascular leakage (1, 35, 44) . One notable aspect of our model is that it lacks a significant inflammatory component (as measured by increased histological and lavage neutrophil infiltration, data not shown). Differences from other models characterized by increased neutrophils (13, 25) can be explained by variations in Fig. 8 . Effect of MV on thrombin-antithrombin complexes (TATc). A: WT mice were exposed to 4-h HVT, and plasma TATc was assessed. MV failed to increase TATc over baseline levels (36.29 vs. 30 .54 g/l; P ϭ 0.70). APC treatment resulted in decreased TATc levels (12.91 g/l), although this was not significant. LPS (intratracheal 3.0 g/g mouse wt, 24 h) resulted in significantly increased TATc (91.93 vs. 30.54 g/l; *P Ͻ 0.01 vs. control; n Ն 3 mice for each group). B-D: Tie2-EPCR mice had significantly less plasma TATc compared with WT under control (8.98 vs. 30.54 g/l; P Ͻ 0.01), HVT (14.44 vs. 36.29 g/l; P Ͻ 0.05), and HVT ϩ APC (1.60 vs. 12.91 g/l; P Ͻ 0.05) conditions. Although there was no significant increase in TATc in Tie2-EPCR mice exposed to HVT MV compared with controls (B vs. C), APC treatment significantly decreased TATc levels in these mice (C vs. D). *P Ͻ 0.05 vs. WT; †P Ͻ 0.05 vs. Tie2-EPCR exposed to HVT MV; n Ն 3 animals per group. tidal volume or MV duration. However, the consistent endothelial barrier dysfunction and capillary leak observed in response to mechanical stress (1, 35, 44) makes our model suitable for in vivo validation of our previous in vitro work on endothelial permeability (16) . There was a small but significant increase in BAL protein at 4-h LV T , however, without any increase in EBD extravasation. Although it is possible that LV T might result in some subtle increase in vascular permeability, it is likely that these changes reflect damage to the alveolar epithelium, whereas EBD leakage reflects endothelial barrier dysfunction.
The present study extends known, in vitro APC-mediated vascular barrier protection to an in vivo model of VILI and potentially provides a mechanistic basis for the protective effect of APC. These findings, taken together with our previous data demonstrating a protective effect of APC in response to thrombin in vitro (16) , suggest that APC-mediated protection is not specific to inflammatory (or coagulation-related) stimuli but also extends to vascular protection against mechanical stress. It is notable that our model results in increased vascular permeability without activating coagulation, as measured by levels of TATc. Not surprisingly, APC decreases TATc, although this was not significant. Furthermore, EPCR-overexpressing mice, which have enhanced protein C conversion to APC and increased endothelial localization of APC (36) , have lower TATc levels compared with WT mice. Although it is possible that enhanced coagulation and thrombin production may be operative in other models of ALI, we found no evidence for APC-mediated protection through decreased thrombin production in our model.
Increasing evidence suggests that ROCK, the downstream effector of the GTPase Rho, plays a role in vascular barrier disruption by agents such as thrombin and VEGF (11, 39, 55) . The Rho pathway promotes actin stress fiber formation resulting in endothelial cell contraction, paracellular gap formation, and increased permeability. Cyclic stretch has been shown to induce the Rho pathway in vitro (53); however, the role of ROCK in stretch-induced permeability in vivo has so far been untested. Our data demonstrate that injurious MV is associated with increased pulmonary ROCK-1 expression. Furthermore, we provide novel data that APC attenuates stretch-induced ROCK expression and that ROCK upregulation in response to MV was absent in EPCR-overexpressing mice. These results suggest that APC-mediated vascular barrier protection involves inhibition of ROCK-1, a mechanism that should be further explored.
These experiments suggest a critical role of EPCR in APC biology and vascular permeability. Structurally similar to the major histocompatibility class I/CD1 family of molecules, EPCR binds protein C, presenting it to the thrombin-thrombomodulin complex, thereby increasing the activation of protein C by ϳ20-fold (17, 42, 56) . Importantly, APC can also bind EPCR, and although the bound form of APC loses its extracellular anticoagulant activity (37), increasing evidence indicates that much, if not all, of APC intracellular signaling is EPCR-dependent. APC inhibits apoptosis and alters endothelial gene expression in an EPCR-dependent manner (12, 48) , and APC-mediated changes in phospho-myosin light chain and barrier protection require EPCR ligation (16) . Inflammatory stimuli result in EPCR shedding form the endothelial surface, and a soluble form of EPCR (sEPCR) is elevated in plasma from patients with sepsis and lupus (33) . Moreover, elevated sEPCR is associated with increased inflammation and tissue injury suggesting that membrane-associated EPCR has some protective effect, perhaps through endogenous APC signaling (52) .
In the present study, we define a temporal relationship between MV-induced pulmonary vascular injury and loss of membrane EPCR, suggesting that loss of tissue EPCR is a critical component of VILI. Moreover, APC therapy is associated with prevention of EPCR downregulation and endothelial barrier protection, even after the onset of mechanical stress. Although significant changes [such as activation of p38 MAPK signaling (1, 35) ] and activation of other signaling processes [e.g., activation of prooxidant enzymes such as inducible nitric oxide synthase (44) and xanthine oxidoreductase (1)] occur within a few minutes of mechanical stress, the effect of APC treatment in protecting against capillary leakage can be delayed after initiation of mechanical stress (as shown in Fig. 3 ) but has to precede EPCR membrane loss (2 h) since APC given at later time points after initiation of MV failed to protect against capillary leakage at 4 h (results not shown). Given that EPCR facilitates protein C activation to APC and serves as the required receptor for APC-mediated endothelial signaling, alterations in tissue EPCR expression have two potentially significant consequences, changes in APC formation (via EPCRfacilitated protein C conversion to APC) and changes in EPCRdependent APC signaling. The notion that EPCR is central to vascular barrier protection is supported by the finding that EPCR-overexpressing mice (obtained from a C57BL/6J background mouse strain) are protected against VILI in our model. Generated with an endothelial-specific Tie2 promoter to target endothelial overexpression of EPCR, these mice have Ͼ100-fold increased pulmonary EPCR expression compared with WT. Furthermore, they have increased EPCR on both pulmonary macro-and microvasculature, a critical feature given that vascular permeability is mediated at the capillary level where EPCR expression is normally relatively low. Despite unchanged protein C mRNA levels, these mice have specific redistribution of protein C to the endothelium and resultant increased protein C activation. Phenotypically normal under basal conditions, Tie2-EPCR mice have improved survival after LPS infusion compared with WT mice (36) . Further evidence of the importance of EPCR in vascular function, EPCR-deficient mice exhibit increased hemodynamic and cardiac derangements as well as increased mortality in response to endotoxin challenge (27) . Our findings are the first to demonstrate that mechanical stress can alter EPCR expression and suggest a dynamic interaction between EPCR and APC: injury is a result of loss of tissue EPCR, whereas APC protects via EPCR stabilization and resultant EPCR-dependent signaling (16) .
Although the effect of MV and VILI on pulmonary gene expression has been recently reported by us and other investigators (22, 41, 43) , the effect of APC treatment on pulmonary gene expression in response to MV has been unexplored. Supportive of our hypothesis and evidence that APC is protective against vascular barrier dysfunction, we demonstrate that APC treatment is associated with downregulation of specific genes that participate in endothelial barrier regulation. For example, MK2 is known to mediate endothelial actin redistribution (30) and increases in vascular permeability (8) induced by hypoxia. This is of particular interest since we (16) have previously demonstrated that APC prevents thrombin-induced actin cytoskeletal changes and is barrier-protective in cultured endothelial cells. Given that endothelial cyclic stretch results in actin redistribution in vitro (7), it is possible that the increased pulmonary vascular leak observed in HV T is via MK2, a mechanism that is under investigation in our laboratory but beyond the scope of the present study.
Similarly, integrin-␤ 6 , which is regulated by APC in our model, is particularly relevant to lung injury. This member of the ␣ v -integrin subfamily is highly expressed in the lungs and has been incriminated in the pathogenesis of ALI induced by lipopolysaccharide and bleomycin (46) . Of note, Jenkins et al. (28) have demonstrated in a mouse model of VILI that ligation of the thrombin receptor protease-activated receptor (PAR)-1 induces integrin-␤ 6 -dependent activation of transforming growth factor-␤ (TGF-␤) and that deletion of integrin-␤ 6 protects against pulmonary edema observed in their VILI model. Integrin-␤ 6 -mediated activation of TGF-␤ has been directly linked to and is dependent on the actin cytoskeleton (40) . Furthermore, integrin-␤ 6 blockade attenuates the barrier disruptive effect and actin stress fiber formation induced by thrombin in endothelial cells. Given the coordinated signaling of APC and thrombin (4, 5, 49) and the known barrier-protective effects of APC on the endothelial cytoskeleton, it is possible that part of the protective effect of APC in VILI seen in our model is via downregulation of integrin-␤ 6 and downstream decreases in activation of TGF-␤. Interestingly, another gene that was downregulated in response to APC treatment was bone morphogenetic protein 1, which is part of the TGF superfamily signaling system and can activate TGF-␤ (19) . In addition, our data indicating that APC downregulates interleukin-1 receptorassociated kinase-2 (IRAK-2), a serine/threonine kinase that associates with the interleukin-1 receptor and participates in Toll-like receptor signaling to activate NF-B (31), supports previous work that APC can alter NF-B expression (29) . Our finding that APC decreases expression of Bcl-2-like-1, a known regulator of apoptosis, is also notable in light of our recent report that VILI is associated with increased alveolar cell apoptosis (35) . Furthermore, our data are supportive of other work that identified increased Bcl-2-like-1 expression in pulmonary endothelium in response to hyperoxia (61) . Finally, we have identified novel potential VILI targets, such as Nr1d1 (Rev-erbalpha), a nuclear receptor involved in maintaining circadian rhythms (15) , which is significantly elevated in mouse lung in response to HV T but returns to normal levels after APC treatment.
In summary, 2 h of HV T MV is required to induce pulmonary vascular permeability and is temporally related to decreased surface EPCR protein expression and increased ROCK-1 expression, whereas treatment with APC significantly attenuates MV-mediated leak and is associated with restoration of tissue EPCR protein and normalization of ROCK-1. These findings, taken together with our previous report that APC enhances pulmonary endothelial barrier function in an EPCRdependent manner, strongly suggest that the protein C system is a crucial participant in vascular barrier homeostasis. Understanding the importance of EPCR in injury development and treatment might lead to novel therapies for ALI.
